Nancy Wareing

TL;DR: Skin in early diffuse SSc has prominent innate and adaptive immune cell signatures that reflect the preceding rate of disease progression, which could have implications in understanding SSc pathogenesis and clinical trial design.

TL;DR: Fibrotic deposition and PH are inhibited by the FDA-approved drug hymecromone, suggesting hyaluronan synthesis inhibition as a potential therapy for CPFE and highlighting a novel mechanism through HAS3-positive macrophages.

TL;DR: In this paper, the authors summarized the known mechanisms that promote pulmonary hypertension in acute respiratory distress syndrome (ARDS) and addressed the implications of PH in the setting of coronavirus disease 2019 (COVID-19).

TL;DR: In this review, existing therapies from the perspective of molecular mechanisms underlying lung fibrosis and vasoconstriction/vascular remodelling are summarized and potential future targets for pharmacotherapy are discussed.

TL;DR: This study implicates the key regulator of alternative polyadenylation, CFIm25 in dermal fibrosis and in systemic sclerosis (scleroderma) pathogenesis, and downregulation promotes the expression of profibrotic factors, exaggerates bleomycin-induced skin fibrosis, while CFIm 25 restoration attenuates skin Fibrosis.